Vienna E Brunt, Jennifer A Miner, Paul F Kaplan, John R Halliwill, Lisa A Strycker, Christopher T Minson
Index: Am. J. Physiol. Heart Circ. Physiol. 305(7) , H1041-9, (2013)
Full Text: HTML
The individual effects of estrogen and progesterone on baroreflex function remain poorly understood. We sought to determine how estradiol (E2) and progesterone (P4) independently alter the carotid-cardiac and carotid-vasomotor baroreflexes in young women by using a hormone suppression and exogenous add-back design. Thirty-two young women were divided into two groups and studied under three conditions: 1) after 4 days of endogenous hormone suppression with a gonadotropin releasing hormone antagonist (control condition), 2) after continued suppression and 3 to 4 days of supplementation with either 200 mg/day oral progesterone (N = 16) or 0.1 to 0.2 mg/day transdermal 17β-estradiol (N = 16), and 3) after continued suppression and 3 to 4 days of supplementation with both hormones. Changes in heart rate (HR), mean arterial pressure (MAP), and femoral vascular conductance (FVC) were measured in response to 5 s of +50 mmHg external neck pressure to unload the carotid baroreceptors. Significant hormone effects on the change in HR, MAP, and FVC from baseline at the onset of neck pressure were determined using mixed model covariate analyses accounting for P4 and E2 plasma concentrations. Neither P4 (P = 0.95) nor E2 (P = 0.95) affected the HR response to neck pressure. Higher P4 concentrations were associated with an attenuated fall in FVC (P = 0.01), whereas higher E2 concentrations were associated with an augmented fall in FVC (P = 0.02). Higher E2 was also associated with an augmented rise in MAP (P = 0.01). We conclude that progesterone blunts whereas estradiol enhances carotid-vasomotor baroreflex sensitivity, perhaps explaining why no differences in sympathetic baroreflex sensitivity are commonly reported between low and high combined hormone phases of the menstrual cycle.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
Ganirelix Acetate
CAS:129311-55-3 |
C84H121ClN18O17 |
Androgens influence microvascular dilation in PCOS through E...
2013-10-01 [Am. J. Physiol. Endocrinol. Metab. 305(7) , E818-25, (2013)] |
GnRH antagonist versus long GnRH agonist protocol in poor IV...
2013-01-01 [Eur. J. Obstet. Gynecol. Reprod. Biol. 166(1) , 43-6, (2013)] |
Outpatient management of severe early OHSS by administration...
2012-01-01 [Reprod. Biol. Endocrinol. 10 , 69, (2012)] |
Replacing GnRH agonists with GnRH antagonists in oocyte reci...
2011-12-01 [Eur. J. Obstet. Gynecol. Reprod. Biol. 159(2) , 355-8, (2011)] |
Analysis of the impact of intravenous LH pulses versus conti...
2012-11-15 [Am. J. Physiol. Regul. Integr. Comp. Physiol. 303(10) , R994-R1002, (2012)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved